Abstract: The invention features a method of diagnosing or providing a prognosis regarding the state of Alzheimer's Disease in a mammal by contacting an ocular tissue with a detectably-labeled compound, which binds to an amyloid protein. An increase in binding of the compound to the ocular tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.
Type:
Grant
Filed:
November 18, 2003
Date of Patent:
November 20, 2007
Assignees:
The General Hospital Corporation, The Brigham and Women's Hospital, Inc.